We are live on ! Find out more
FBRX icon

Forte Biosciences
FBRX

49 hedge funds and large institutions have $306M invested in Forte Biosciences in 2020 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 7 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

171% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 7

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

4% more funds holding

Funds holding: 47 → 49 (+2)

0.19% more ownership

Funds ownership: 2.43% → 2.62% (+0.19%)

7% less capital invested

Capital invested by funds: $330M → $306M (-$24.5M)

Holders
49
Holders Change
+2
Holders Change %
+4.26%
% of All Funds
0.87%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
19
Reduced
7
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$13.2M
2
SCM
Suvretta Capital Management
New York
+$12.2M
3
Invesco
Invesco
Georgia
+$10.6M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$10.5M
5
WP
Woodline Partners
California
+$7.23M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$9.34M
2
CS
Credit Suisse
Switzerland
-$3.59M
3
BI
BVF Inc
California
-$2.21M
4
EGI
EAM Global Investors
California
-$1.5M
5
EI
EAM Investors
California
-$1.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACH
1
ArrowMark Colorado Holdings
Colorado
$107M – – –
Franklin Resources
2
Franklin Resources
California
$38.4M +$3.2M +3,401 +9%
BI
3
BVF Inc
California
$26.2M -$2.21M -2,350 -8%
FAM
4
Fred Alger Management
New York
$17.6M +$647K +688 +4%
Vanguard Group
5
Vanguard Group
Pennsylvania
$16.2M +$10.5M +11,151 +169%
Citadel Advisors
6
Citadel Advisors
Florida
$13.1M +$757K +805 +6%
PA
7
Perceptive Advisors
New York
$12.7M +$13.2M +14,000 New
SCM
8
Suvretta Capital Management
New York
$11.8M +$12.2M +13,000 New
Invesco
9
Invesco
Georgia
$11M +$10.6M +11,238 +1,364%
WP
10
Woodline Partners
California
$7M +$7.23M +7,691 New
BlackRock
11
BlackRock
New York
$5.51M +$1.73M +1,843 +44%
O
12
OrbiMed
New York
$3.36M -$9.34M -9,931 -73%
CS
13
Credit Suisse
Switzerland
$3.1M -$3.59M -3,818 -53%
Point72 Asset Management
14
Point72 Asset Management
Connecticut
$3.1M +$3.2M +3,400 New
ACM
15
Asymmetry Capital Management
California
$3.09M +$195K +207 +6%
MS
16
Maven Securities
Jersey
$3.04M +$3.13M +3,335 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$2.84M +$57.3K +61 +2%
PVI
18
Pura Vida Investments
New York
$2.37M +$2.44M +2,600 New
SC
19
Sepio Capital
Utah
$2.13M +$1.51M +1,608 +218%
6CM
20
683 Capital Management
New York
$1.66M +$1.72M +1,825 New
GPCM
21
Granite Point Capital Management
Massachusetts
$1.6M +$1.65M +1,760 New
Millennium Management
22
Millennium Management
New York
$1.42M +$1.47M +1,561 New
Qube Research & Technologies (QRT)
23
Qube Research & Technologies (QRT)
United Kingdom
$1.2M -$399K -424 -24%
PHP
24
Parkman Healthcare Partners
Connecticut
$1.13M +$699K +744 +149%
ECM
25
ExodusPoint Capital Management
New York
$1.09M +$1.12M +1,193 New
1
2 3

FBRX Hedge Fund Activity: Q4 2020 in Review

49 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Forte Biosciences (FBRX) for Q4 2020, worth a combined $306M — down 7.4% from $330M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new FBRX positions and 13 closed out — a net gain of 2 holders — while 19 added to existing stakes and 7 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $13.2M. The largest seller was OrbiMed, cutting an estimated $9.34M.

  • 49 institutional investors held Forte Biosciences (FBRX) as of Q4 2020, up from 47 in Q3 2020.
  • Funds reported $306M of Forte Biosciences stock for Q4 2020, down 7.4% quarter-over-quarter.
  • 15 funds opened new Forte Biosciences positions in Q4 2020 and 13 closed out, a net change of +2 holders.
  • The largest Forte Biosciences buyer in Q4 2020 was Perceptive Advisors, an estimated $13.2M added.
  • The largest Forte Biosciences seller in Q4 2020 was OrbiMed, an estimated $9.34M sold.

Based on aggregated 13F filings for Q4 2020.